Healthcare Industry News: Monaco
News Release - June 10, 2010
Elekta Launches New Version of Monaco Treatment Planning System Designed for Elekta VMAT Delivery
Advanced arc therapy delivery technique further optimized with gold standard planning, helping doctors to provide best possible treatment for patientsATLANTA, June 10 -- (Healthcare Sales & Marketing Network) -- Elekta recently announced the latest production release of its Monaco® treatment planning system, version 2.03, which is designed to enhance planning for Elekta VMAT. Monaco provides key features that aid clinicians in planning around structures effectively for Elekta VMAT delivery and accurately predict the total dose the patient will receive.
Monaco helps indicate where clinicians can improve Elekta VMAT plans, according to Rob Cessac, Product Manager, Elekta Software. "By using biological optimization and Monte Carlo dose calculations, Monaco VMAT can help clinicians design timely and accurate treatment plans," he says. "The resulting plans are of similar quality to IMRT, but can be delivered in much less time, enabling a more efficient clinic and a better patient experience."
In advance of the full launch of Monaco 2.03, sites in Asia, Central America, Europe and the United States have clinically implemented the planning system for Elekta VMAT delivery.
For additional information, visit www.elekta.com/Monacovmat.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible today.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
Source: Elekta
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
